...
首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
【24h】

Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.

机译:常染色体显性遗传性多囊肾病高血压患者的血管紧张素转化酶抑制作用逆转左室肥大。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Hypertension occurs commonly and early in the natural history of autosomal dominant polycystic kidney disease (ADPKD), affecting both renal and patient outcome. Activation of the renin angiotensin aldosterone system due to cyst expansion and local renal ischaemia plays an important role in the development of ADPKD related hypertension and left ventricular hypertrophy (LVH), a known important risk factor for cardiovascular morbidity and mortality. The aim of this study was to investigate the effects of an angiotensin converting enzyme (ACE) inhibitor, enalapril, on renal function, blood pressure and LVH in hypertensive ADPKD patients. METHODS: Fourteen hypertensive ADPKD patients (11 men, 3 women; mean age: 40 years) were included in the study. All patients had LVH and creatinine clearance (Cer) greater than 50 ml/min/1.73 m2. The patients were followed for 7 years on enalapril therapy. The effects of enalapril on renal function, blood pressure and LVH were investigated. RESULTS: Baseline measurements of mean arterial pressure (MAP), Ccr and left ventricular mass index (LVMI) were 110 +/- 2 mmHg, 84 +/- 6 ml/min/1.73 m2 and 146 +/- 4 g/m2, respectively. After one year of enalapril therapy there was a significant decrease in MAP (94 +/- 3 mmHg, P < 0.005) which remained stable until the end of the study at 7 years (94 +/- 1 mmHg, P < 0.005 vs baseline). There was also a significant decrease in LVMI (131 +/- 6 g/m2, P < 0.05) after year 1 which continued to decrease until the end of the study reaching 98 +/- 6 g/m2 (P < 0.01 vs year 1 and baseline). Although Ccr remained stable after year 1, a significant decrease was observed after 7 years of follow-up (59 +/- 6 ml/min, P < 0.001 vs year 1 and baseline). CONCLUSIONS: ACE inhibition in hypertensive ADPKD patients provided long-term reversal of LVH in association with a mean 3.6 ml/min/year decline of Ccr. These preliminary results have potential important implications for cardiovascular and renal protection in ADPKD.
机译:背景:高血压常发生于常染色体显性多囊肾疾病(ADPKD)的自然史中,并影响肾脏和患者的预后。由于囊肿扩张和局部肾缺血导致的肾素血管紧张素醛固酮系统的激活在与ADPKD相关的高血压和左心室肥大(LVH)的发展中起着重要作用,这是已知的心血管疾病发病率和死亡率的重要危险因素。这项研究的目的是研究血管紧张素转换酶(ACE)抑制剂依那普利对高血压ADPKD患者肾功能,血压和LVH的影响。方法:该研究纳入了14名高血压ADPKD患者(男11例,女3例;平均年龄:40岁)。所有患者的LVH和肌酐清除率(Cer)均大于50 ml / min / 1.73 m2。患者接受依那普利治疗7年。研究了依那普利对肾功能,血压和LVH的影响。结果:基线平均动脉压(MAP),Ccr和左心室质量指数(LVMI)为110 +/- 2 mmHg,84 +/- 6 ml / min / 1.73 m2和146 +/- 4 g / m2,分别。依那普利治疗一年后,MAP显着降低(94 +/- 3 mmHg,P <0.005),直到研究结束第7年均保持稳定(94 +/- 1 mmHg,P <0.005) )。第1年后LVMI也显着下降(131 +/- 6 g / m2,P <0.05),并持续下降直至研究结束,达到98 +/- 6 g / m2(P <0.01 vs. 1和基准)。尽管Ccr在第1年后保持稳定,但在随访7年后观察到显着下降(59 +/- 6 ml / min,相对于第1年和基线,P <0.001)。结论:高血压ADPKD患者的ACE抑制可长期逆转LVH,平均Ccr下降3.6 ml / min /年。这些初步结果对ADPKD的心血管和肾脏保护具有潜在的重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号